Illumina, Inc. $ILMN Shares Sold by Aberdeen Group plc

Aberdeen Group plc lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 28.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 234,394 shares of the life sciences company’s stock after selling 92,965 shares during the period. Aberdeen Group plc owned 0.15% of Illumina worth $22,260,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P grew its holdings in Illumina by 1.9% in the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after buying an additional 78,317 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the period. Geode Capital Management LLC boosted its position in shares of Illumina by 0.7% in the second quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after acquiring an additional 21,342 shares during the last quarter. Bank of America Corp DE grew its holdings in Illumina by 1.9% in the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares during the period. Finally, Edmond DE Rothschild Holding S.A. grew its holdings in Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after purchasing an additional 833,750 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Evercore set a $150.00 price target on shares of Illumina in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. UBS Group reiterated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Canaccord Genuity Group boosted their price target on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research report on Monday, January 26th. Finally, Piper Sandler cut their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Illumina currently has an average rating of “Hold” and an average target price of $127.94.

Illumina Price Performance

ILMN opened at $116.51 on Wednesday. The company has a fifty day simple moving average of $136.77 and a 200 day simple moving average of $116.89. The firm has a market cap of $17.81 billion, a price-to-earnings ratio of 21.38, a PEG ratio of 2.23 and a beta of 1.45. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Scott M. Davies sold 323 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.17% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.